Sirio Pharma to boost Australian growth with new GMP certificate
Image credit: Sirio PharmaSirio Pharma’s largest manufacturing facility in Ma’anshan, China, has received a Certificate of GMP (Good Manufacturing Practices) Compliance from Australia’s Therapeutic Goods Administration (TGA). The company says this approval will support its expansion into the growing Australian market.
Australian brands can now partner with Sirio to gain access to its solutions and research to accelerate new product development.
The approval confirms that Sirio meets TGA’s GMP requirements for the manufacturing of non-sterile listed therapeutic goods, such as pastilles, oral liquids, and powders. The certification covers end-to-end finished product manufacturing, ensuring that products exceed TGA’s safety, consistency, and quality standards.
“Achieving TGA GMP certification at our Ma’anshan facility is a key step in Sirio’s strategic expansion into the Australian market,” comments Ryan Li, head of Quality at Sirio. “It reflects our commitment to help brands develop new formulations tailored to the needs of Australian consumers while meeting both international and national regulatory standards.”
APAC expansion
The Ma’anshan site is Sirio’s most advanced facility, with an annual production capacity of up to 2.4 billion gummies, 80 million functional drink bags, and 34 million bottles of nutritional powders. It supports large-scale commercial manufacturing and flexible customized production.
Earlier this year, the company announced plans to build a new manufacturing site in Thailand to expand its reach in Southeast Asia. The contract development and manufacturing organization noted that APAC revenues (excluding China) increased by 77% year-on-year and identified Australia as a key growth driver for the next five years.
The new certification allows the company to fast-track collaborations with Australian brands and supports international brands with options to access the Australian market.
